Syndax Pharmaceuticals Inc (SNDX): Next-Year EPS Estimate 67.12%
As of 2026-06-04, Syndax Pharmaceuticals Inc (SNDX) has a next-year EPS growth estimate of 67.12%.
On 2026-06-03, analyst consensus for SNDX's next-year EPS growth shifted from 67.11% to 67.12% — a positive change of 0.01 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 45.70%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 67.12%
- EPS growth this year
- 45.70%
- EPS next quarter (est)
- -$0.48
- Last price
- $18.02
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 67.12% | 45.70% | -$0.48 | $18.02 |
| 2026-06-03 | 67.12% | 45.70% | -$0.48 | $18.34 |
| 2026-06-02 | 67.11% | 45.70% | -$0.48 | $18.39 |
| 2026-06-01 | 67.11% | 45.70% | -$0.48 | $18.85 |
| 2026-05-31 | 67.11% | 45.70% | -$0.48 | $19.59 |
| 2026-05-28 | 67.11% | 45.70% | -$0.48 | $19.75 |
| 2026-05-27 | 67.11% | 45.70% | -$0.48 | $19.61 |
| 2026-05-26 | 67.11% | 45.70% | -$0.48 | $19.90 |
| 2026-05-25 | 67.11% | 45.70% | -$0.48 | $19.94 |
| 2026-05-24 | 67.11% | 45.70% | -$0.48 | $19.94 |
| 2026-05-21 | 67.11% | 45.70% | -$0.48 | $19.77 |
| 2026-05-20 | 67.11% | 45.70% | -$0.48 | $20.13 |
| 2026-05-19 | 67.11% | 45.70% | -$0.48 | $19.36 |
| 2026-05-18 | 67.11% | 45.70% | -$0.48 | $19.41 |
| 2026-05-17 | 67.11% | 45.70% | -$0.48 | $20.23 |
| 2026-05-14 | 67.11% | 45.70% | -$0.48 | $20.55 |
| 2026-05-13 | 67.73% | 44.74% | -$0.48 | $20.94 |
| 2026-05-12 | 69.33% | 45.26% | -$0.48 | $20.41 |
| 2026-05-11 | 69.33% | 45.26% | -$0.48 | $21.38 |
| 2026-05-10 | 69.33% | 45.26% | -$0.48 | $21.49 |
| 2026-05-07 | 69.33% | 45.26% | -$0.48 | $20.54 |
| 2026-05-06 | 69.69% | 46.13% | -$0.47 | $20.65 |
| 2026-05-05 | 69.69% | 46.13% | -$0.47 | $20.10 |
| 2026-05-04 | 69.69% | 46.13% | -$0.47 | $19.96 |
| 2026-05-03 | 69.69% | 46.13% | -$0.47 | $19.11 |
| 2026-04-30 | 68.30% | 45.21% | -$0.61 | $21.43 |
| 2026-04-29 | 68.41% | 45.27% | -$0.61 | $20.63 |
| 2026-04-28 | 68.41% | 45.27% | -$0.61 | $21.11 |
| 2026-04-27 | 68.41% | 45.27% | -$0.61 | $21.00 |
| 2026-04-26 | 68.41% | 45.27% | -$0.61 | $21.39 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Syndax Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Syndax Pharmaceuticals Inc (SNDX) has a next-year EPS growth estimate of 67.12%, based on analyst consensus.
When was the latest EPS estimate revision for SNDX?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 67.11% to 67.12%.
What sector and industry does Syndax Pharmaceuticals Inc belong to?▾
Syndax Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. SNDX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Syndax Pharmaceuticals Inc (SNDX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports